Vienna, Austria, June 18, 2020 – AFFiRiS AG, a clinical-stage biotechnology company developing novel disease-modifying specific active immunotherapies (SAITs), today announced that detailed results of the phase 1 clinical program with its lead candidate PD01 in early Parkinson’s disease (PD) patients were published in the peer-reviewed journal The Lancet Neurology. The results of the long-term...
Tag: <span>Novel dementia</span>
Post
Novel dementia vaccine on track for human trials within two years
By Rich Haridy A newly published study has described the successful results in mice of a novel vaccine designed to prevent neurodegeneration associated with Alzheimer’s disease. The researchers suggest this “dementia vaccine” is now ready for human trials, and if successful could become the “breakthrough of the next decade.” The new study, led by the...